When starting amikacin liposome inhalation suspension, how and for what duration do you monitor the patient for microbial conversion and response to therapy?

When starting amikacin liposome inhalation suspension, how and for what duration do you monitor the patient for microbial conversion and response to therapy?

When starting amikacin liposome inhalation suspension, how and for what duration do you monitor the patient for microbial conversion and response to therapy?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Mehdi Mirsaeidi, MD, MPH

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary